ADCC (antibody-dependent cellular cytotoxicity)

In ADCC, an antibody flags a cell, and NK cells recognise the flag and kill it.

Mediated by Fc–FcγRIIIa (CD16) interaction. Enhanced by afucosylation (obinutuzumab, margetuximab, belantamab). Contributes to trastuzumab, rituximab, and cetuximab activity.

Immunology: what this kind of term is about · animated schematic, not to scale

Key papers

1top

rctThe Lancet 2023changed practice

SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer

Patients with newly diagnosed advanced stomach cancer should now have Claudin 18.2 tested alongside HER2, PD-L1 and mismatch repair, because roughly a third will be eligible for zolbetuximab, which adds about three months of median survival. The main practical problem is nausea and vomiting during infusions, which needs aggressive prophylaxis. How to sequence or combine it with immunotherapy in PD-L1-positive tumours is unresolved.

Connected

22top

ADCC (antibody-dependent cellular cytotoxicity)

Key papers

Connected

cancers

technologies

targets

drugs

institutions

pathways

terms

key papers